niacinamide has been researched along with Insulin Resistance in 50 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Insulin Resistance: Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Loganin is an iridoid glycoside with antioxidant, anti-inflammatory, glucose-lowering activities which may address the pathological mechanisms of painful diabetic neuropathy (PDN) related to inflammation, oxidative stress, and hyperglycemia." | 8.02 | Loganin Ameliorates Painful Diabetic Neuropathy by Modulating Oxidative Stress, Inflammation and Insulin Sensitivity in Streptozotocin-Nicotinamide-Induced Diabetic Rats. ( Cheng, YC; Chiu, YM; Dai, ZK; Wu, BN, 2021) |
| "Current studies aimed at investigating the association between atorvastatin therapy and insulin resistance (IR) appear to be controversial." | 7.96 | Long-term atorvastatin or the combination of atorvastatin and nicotinamide ameliorate insulin resistance and left ventricular diastolic dysfunction in a murine model of obesity. ( Mao, Y; Ning, D; Tang, S; Wang, D; Wang, T; Xiong, T; Yang, X; Zhong, H; Zhu, G, 2020) |
| "Resveratrol improves insulin sensitivity and lowers hepatic glucose production (HGP) in rat models of obesity and diabetes, but the underlying mechanisms for these antidiabetic effects remain elusive." | 7.81 | Resveratrol activates duodenal Sirt1 to reverse insulin resistance in rats through a neuronal network. ( Baur, JA; Breen, DM; Côté, CD; Daljeet, M; Duca, FA; Filippi, BM; Lam, TK; Rasmussen, BA; Zadeh-Tahmasebi, M, 2015) |
| "To investigate nicotinamide's action on glucose metabolism, and the association between niacin consumption and obesity prevalence." | 7.76 | Chronic niacin overload may be involved in the increased prevalence of obesity in US children. ( Bian, FN; Guo, M; Li, D; Liu, QG; Luo, N; Sun, WP; Zhao, ZG; Zhou, SS; Zhou, YM, 2010) |
| " The likely involvement of the kinase pathway is implicated in the unique effects of nicotinamide riboside in raising tissue NAD concentrations in rodents and for potent effects in eliciting insulin sensitivity, mitochondrial biogenesis, and enhancement of sirtuin functions." | 4.89 | Nicotinamide riboside, a trace nutrient in foods, is a vitamin B3 with effects on energy metabolism and neuroprotection. ( Chi, Y; Sauve, AA, 2013) |
| " The most widely employed activator is resveratrol, a small polyphenol that improves insulin sensitivity and vascular function, boosts endurance, inhibits tumor formation, and ameliorates the early mortality associated with obesity in mice." | 4.86 | Biochemical effects of SIRT1 activators. ( Baur, JA, 2010) |
| "Loganin is an iridoid glycoside with antioxidant, anti-inflammatory, glucose-lowering activities which may address the pathological mechanisms of painful diabetic neuropathy (PDN) related to inflammation, oxidative stress, and hyperglycemia." | 4.02 | Loganin Ameliorates Painful Diabetic Neuropathy by Modulating Oxidative Stress, Inflammation and Insulin Sensitivity in Streptozotocin-Nicotinamide-Induced Diabetic Rats. ( Cheng, YC; Chiu, YM; Dai, ZK; Wu, BN, 2021) |
| "Current studies aimed at investigating the association between atorvastatin therapy and insulin resistance (IR) appear to be controversial." | 3.96 | Long-term atorvastatin or the combination of atorvastatin and nicotinamide ameliorate insulin resistance and left ventricular diastolic dysfunction in a murine model of obesity. ( Mao, Y; Ning, D; Tang, S; Wang, D; Wang, T; Xiong, T; Yang, X; Zhong, H; Zhu, G, 2020) |
| " After administration of different concentrations and molecular weights of β-d-glucan by oral gavage for 28 days, the body weight, fasting blood glucose, serum insulin, hepatic glycogen, glucose kinase and glucose-6-phosphatase activity of the diabetic mice were measured." | 3.83 | The anti-diabetic activity of oat β-d-glucan in streptozotocin-nicotinamide induced diabetic mice. ( Hu, B; Liu, M; Qi, X; Qian, H; Wang, L; Zhang, H; Zhang, Y, 2016) |
| "Resveratrol improves insulin sensitivity and lowers hepatic glucose production (HGP) in rat models of obesity and diabetes, but the underlying mechanisms for these antidiabetic effects remain elusive." | 3.81 | Resveratrol activates duodenal Sirt1 to reverse insulin resistance in rats through a neuronal network. ( Baur, JA; Breen, DM; Côté, CD; Daljeet, M; Duca, FA; Filippi, BM; Lam, TK; Rasmussen, BA; Zadeh-Tahmasebi, M, 2015) |
| "Ecological evidence suggests that niacin (nicotinamide and nicotinic acid) fortification may be involved in the increased prevalence of obesity and type 2 diabetes, both of which are associated with insulin resistance and epigenetic changes." | 3.79 | Nicotinamide supplementation induces detrimental metabolic and epigenetic changes in developing rats. ( Cao, JM; Cao, Y; Gong, XJ; Guo, J; Guo, M; Li, D; Lun, YZ; Luo, N; Sun, WP; Tian, YJ; Zhou, SS, 2013) |
| "To investigate nicotinamide's action on glucose metabolism, and the association between niacin consumption and obesity prevalence." | 3.76 | Chronic niacin overload may be involved in the increased prevalence of obesity in US children. ( Bian, FN; Guo, M; Li, D; Liu, QG; Luo, N; Sun, WP; Zhao, ZG; Zhou, SS; Zhou, YM, 2010) |
| " No serious adverse events due to NR supplementation were observed and safety blood tests were normal." | 2.87 | A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects. ( Brenner, C; Christensen, B; Dollerup, OL; Jessen, N; Møller, N; Ringgaard, S; Schmidt, MS; Stødkilde-Jørgensen, H; Sulek, K; Svart, M; Treebak, JT, 2018) |
| "Patients with manifest type 2 diabetes have a significantly (approximately twofold) higher NNMT expression both in omental and subcutaneous WAT compared with controls." | 2.80 | Association of nicotinamide-N-methyltransferase mRNA expression in human adipose tissue and the plasma concentration of its product, 1-methylnicotinamide, with insulin resistance. ( Blüher, M; Dietrich, A; Kannt, A; Klöting, N; Pfenninger, A; Schön, MR; Teichert, L; Tönjes, A, 2015) |
| "Metformin is a first-line therapeutic option for the treatment of type 2 diabetes, even though its underlying mechanisms of action are relatively unclear." | 1.42 | Metformin activates a duodenal Ampk-dependent pathway to lower hepatic glucose production in rats. ( Côté, CD; Duca, FA; Filippi, BM; Lam, TK; Rasmussen, BA; Rutter, GA; Zadeh-Tahmasebi, M, 2015) |
| "In obesity and type 2 diabetes, Glut4 glucose transporter expression is decreased selectively in adipocytes." | 1.40 | Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity. ( Alhonen, L; Asara, JM; Banks, AS; Bhanot, S; Cen, Y; Gong, F; Kahn, BB; Kong, D; Kraus, D; Monia, BP; Peroni, OD; Pirinen, E; Puigserver, P; Pulinilkunnil, TC; Rodgers, JT; Sauve, AA; Wang, YC; Yang, Q; Zhang, L, 2014) |
| " At the same dosage (2 g/kg), in comparison with nicotinamide, nicotinic acid was weaker in raising plasma N(1)-methylnicotinamide levels (0." | 1.39 | Excessive nicotinic acid increases methyl consumption and hydrogen peroxide generation in rats. ( Cao, Y; Li, D; Li, SZ; Luo, N; Ma, Q; Shi, Q; Zhou, SS, 2013) |
| "Since blood levels of ADN are low in type 2 diabetes mellitus (DM), this study was designed to investigate the therapeutic effectiveness of increasing the ADN level through injection of plasmid DNA encoding ADN in type 2 DM." | 1.36 | Construction of adiponectin-encoding plasmid DNA and gene therapy of non-obese type 2 diabetes mellitus. ( Myung, CS; Nan, MH; Park, JS, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (4.00) | 18.2507 |
| 2000's | 6 (12.00) | 29.6817 |
| 2010's | 30 (60.00) | 24.3611 |
| 2020's | 12 (24.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, YC | 1 |
| Chiu, YM | 1 |
| Dai, ZK | 1 |
| Wu, BN | 1 |
| Wu, S | 1 |
| Ai, W | 1 |
| Nie, L | 1 |
| Lu, X | 1 |
| Kong, ZL | 1 |
| Sudirman, S | 1 |
| Hsu, YC | 1 |
| Su, CY | 1 |
| Kuo, HP | 1 |
| Sambeat, A | 1 |
| Ratajczak, J | 1 |
| Joffraud, M | 1 |
| Sanchez-Garcia, JL | 1 |
| Giner, MP | 1 |
| Valsesia, A | 1 |
| Giroud-Gerbetant, J | 1 |
| Valera-Alberni, M | 1 |
| Cercillieux, A | 1 |
| Boutant, M | 1 |
| Kulkarni, SS | 1 |
| Moco, S | 1 |
| Canto, C | 1 |
| Dollerup, OL | 2 |
| Chubanava, S | 1 |
| Agerholm, M | 1 |
| Søndergård, SD | 1 |
| Altıntaş, A | 1 |
| Møller, AB | 1 |
| Høyer, KF | 1 |
| Ringgaard, S | 2 |
| Stødkilde-Jørgensen, H | 2 |
| Lavery, GG | 2 |
| Barrès, R | 1 |
| Larsen, S | 1 |
| Prats, C | 1 |
| Jessen, N | 2 |
| Treebak, JT | 2 |
| Bayat, M | 1 |
| Alaee, M | 1 |
| Akbari, A | 1 |
| Sadegh, M | 1 |
| Latifi, SA | 1 |
| Parastesh, M | 1 |
| Salehi, M | 1 |
| Karami, H | 1 |
| Amri, J | 1 |
| Kalidhindi, S | 1 |
| Uddandrao, VVS | 1 |
| Sasikumar, V | 1 |
| Raveendran, N | 1 |
| Ganapathy, S | 1 |
| Zhang, J | 2 |
| Chen, Y | 2 |
| Liu, C | 2 |
| Li, L | 2 |
| Li, P | 2 |
| Yang, X | 1 |
| Xiong, T | 1 |
| Ning, D | 1 |
| Wang, T | 1 |
| Zhong, H | 1 |
| Tang, S | 1 |
| Mao, Y | 1 |
| Zhu, G | 1 |
| Wang, D | 1 |
| Abdel-Aal, RA | 1 |
| Abdel-Rahman, MS | 1 |
| Al Bayoumi, S | 1 |
| Ali, LA | 1 |
| de Castro, JM | 1 |
| Assumpção, JAF | 1 |
| Stein, DJ | 1 |
| Toledo, RS | 1 |
| da Silva, LS | 1 |
| Caumo, W | 1 |
| Carraro, CC | 1 |
| da Rosa Araujo, AS | 1 |
| Torres, ILS | 1 |
| Hardy, RS | 1 |
| Botfield, H | 1 |
| Markey, K | 1 |
| Mitchell, JL | 1 |
| Alimajstorovic, Z | 1 |
| Westgate, CSJ | 1 |
| Sagmeister, M | 1 |
| Fairclough, RJ | 1 |
| Ottridge, RS | 1 |
| Yiangou, A | 1 |
| Storbeck, KH | 1 |
| Taylor, AE | 1 |
| Gilligan, LC | 1 |
| Arlt, W | 1 |
| Stewart, PM | 1 |
| Tomlinson, JW | 1 |
| Mollan, SP | 1 |
| Sinclair, AJ | 1 |
| Roberti, A | 1 |
| Fernández, AF | 1 |
| Fraga, MF | 1 |
| Kazemi, F | 1 |
| Zahediasl, S | 1 |
| Fan, R | 1 |
| Cui, J | 1 |
| Ren, F | 1 |
| Wang, Q | 1 |
| Huang, Y | 1 |
| Zhao, B | 1 |
| Wei, L | 1 |
| Qian, X | 1 |
| Xiong, X | 1 |
| Christensen, B | 1 |
| Svart, M | 1 |
| Schmidt, MS | 1 |
| Sulek, K | 1 |
| Møller, N | 1 |
| Brenner, C | 2 |
| Shah, MA | 1 |
| Reanmongkol, W | 1 |
| Radenahmad, N | 1 |
| Khalil, R | 1 |
| Ul-Haq, Z | 1 |
| Panichayupakaranant, P | 1 |
| El-Beih, NM | 1 |
| Ramadan, G | 1 |
| El-Husseiny, EA | 1 |
| Hussein, AM | 1 |
| Li, D | 5 |
| Tian, YJ | 2 |
| Guo, J | 1 |
| Sun, WP | 2 |
| Lun, YZ | 1 |
| Guo, M | 3 |
| Luo, N | 3 |
| Cao, Y | 3 |
| Cao, JM | 1 |
| Gong, XJ | 1 |
| Zhou, SS | 5 |
| Chi, Y | 1 |
| Sauve, AA | 2 |
| Yang, SJ | 1 |
| Choi, JM | 1 |
| Kim, L | 1 |
| Park, SE | 1 |
| Rhee, EJ | 1 |
| Lee, WY | 1 |
| Oh, KW | 1 |
| Park, SW | 1 |
| Park, CY | 1 |
| Kraus, D | 1 |
| Yang, Q | 1 |
| Kong, D | 1 |
| Banks, AS | 1 |
| Zhang, L | 1 |
| Rodgers, JT | 1 |
| Pirinen, E | 1 |
| Pulinilkunnil, TC | 1 |
| Gong, F | 1 |
| Wang, YC | 1 |
| Cen, Y | 1 |
| Asara, JM | 1 |
| Peroni, OD | 1 |
| Monia, BP | 1 |
| Bhanot, S | 1 |
| Alhonen, L | 1 |
| Puigserver, P | 1 |
| Kahn, BB | 1 |
| Nayak, Y | 1 |
| Hillemane, V | 1 |
| Daroji, VK | 1 |
| Jayashree, BS | 1 |
| Unnikrishnan, MK | 1 |
| Kannt, A | 2 |
| Pfenninger, A | 2 |
| Teichert, L | 1 |
| Tönjes, A | 2 |
| Dietrich, A | 1 |
| Schön, MR | 1 |
| Klöting, N | 1 |
| Blüher, M | 2 |
| Côté, CD | 2 |
| Rasmussen, BA | 2 |
| Duca, FA | 2 |
| Zadeh-Tahmasebi, M | 2 |
| Baur, JA | 2 |
| Daljeet, M | 1 |
| Breen, DM | 1 |
| Filippi, BM | 2 |
| Lam, TK | 2 |
| Rutter, GA | 1 |
| Zhou, Y | 1 |
| Polakof, S | 1 |
| Dardevet, D | 1 |
| Lyan, B | 1 |
| Mosoni, L | 1 |
| Gatineau, E | 1 |
| Martin, JF | 1 |
| Pujos-Guillot, E | 1 |
| Mazur, A | 1 |
| Comte, B | 1 |
| Trammell, SA | 1 |
| Weidemann, BJ | 1 |
| Chadda, A | 1 |
| Yorek, MS | 1 |
| Holmes, A | 1 |
| Coppey, LJ | 1 |
| Obrosov, A | 1 |
| Kardon, RH | 1 |
| Yorek, MA | 1 |
| Liu, M | 1 |
| Zhang, Y | 1 |
| Zhang, H | 1 |
| Hu, B | 1 |
| Wang, L | 1 |
| Qian, H | 1 |
| Qi, X | 1 |
| Qi, Z | 1 |
| Xia, J | 1 |
| Xue, X | 1 |
| He, Q | 1 |
| Ji, L | 1 |
| Ding, S | 1 |
| Matsuyama-Yokono, A | 2 |
| Tahara, A | 2 |
| Nakano, R | 1 |
| Someya, Y | 1 |
| Hayakawa, M | 1 |
| Shibasaki, M | 2 |
| Nan, MH | 1 |
| Park, JS | 1 |
| Myung, CS | 1 |
| Zhou, YM | 1 |
| Liu, QG | 1 |
| Bian, FN | 1 |
| Zhao, ZG | 1 |
| Liu, XX | 1 |
| Sun, CB | 1 |
| Yang, TT | 1 |
| Li, CY | 1 |
| Arya, A | 1 |
| Cheah, SC | 1 |
| Looi, CY | 1 |
| Taha, H | 1 |
| Mustafa, MR | 1 |
| Mohd, MA | 1 |
| Ma, Q | 1 |
| Li, SZ | 1 |
| Shi, Q | 1 |
| Perez-Gutierrez, RM | 1 |
| Damian-Guzman, M | 1 |
| Ferreira, MR | 1 |
| Camberos, Mdel C | 1 |
| Selenscig, D | 1 |
| Martucci, LC | 1 |
| Chicco, A | 1 |
| Lombardo, YB | 1 |
| Cresto, JC | 1 |
| Maruyama, T | 1 |
| Broca, C | 1 |
| Breil, V | 1 |
| Cruciani-Guglielmacci, C | 1 |
| Manteghetti, M | 1 |
| Rouault, C | 1 |
| Derouet, M | 1 |
| Rizkalla, S | 1 |
| Pau, B | 1 |
| Petit, P | 1 |
| Ribes, G | 1 |
| Ktorza, A | 1 |
| Gross, R | 1 |
| Reach, G | 1 |
| Taouis, M | 1 |
| Nakamura, T | 1 |
| Terajima, T | 1 |
| Ogata, T | 1 |
| Ueno, K | 1 |
| Hashimoto, N | 1 |
| Ono, K | 1 |
| Yano, S | 1 |
| Vital, P | 1 |
| Larrieta, E | 1 |
| Hiriart, M | 1 |
| Bingley, PJ | 1 |
| Mahon, JL | 1 |
| Gale, EA | 1 |
| Greenbaum, CJ | 1 |
| Kahn, SE | 1 |
| Palmer, JP | 1 |
| Ogino, T | 1 |
| Zhu, M | 1 |
| Murakami, T | 1 |
| Kuwajima, M | 1 |
| Shima, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effect of Nicotinamide Ribose (NR) on Substrate Metabolism, Insulin Sensitivity, and Body Composition in Obese Men - a Randomized, Placebo Controlled Clinical Trial[NCT02303483] | 40 participants (Actual) | Interventional | 2016-01-04 | Completed | |||
| Lowering Intracranial Pressure in Idiopathic Intracranial Hypertension: Assessing the Therapeutic Efficacy and Safety of an 11β-hydroxysteroid Dehydrogenase Type 1 Inhibitor (AZD4017). Phase II Study.[NCT02017444] | Phase 2 | 31 participants (Actual) | Interventional | 2014-04-25 | Completed | ||
| Center-Based and Home-Based Walking Exercise Intervention to Reduce Fatigue in Older Breast Cancer Survivors[NCT05684367] | 24 participants (Anticipated) | Interventional | 2023-11-29 | Recruiting | |||
| NOPARK Open Label Extension Study[NCT05546567] | 400 participants (Anticipated) | Interventional | 2022-09-28 | Recruiting | |||
| Validation of an Enzymatic Assay for Quantification of Nicotinamide Adenine Dinucleotide in Blood Plasma After Ingestion of the Vitamin B3 Variant Nicotinamide Riboside: a Randomized Controlled Trial[NCT06005350] | 54 participants (Anticipated) | Interventional | 2023-11-01 | Recruiting | |||
| Nicotinamide Riboside (NR) in Paclitaxel-induced Peripheral Neuropathy[NCT03642990] | Phase 2 | 5 participants (Actual) | Interventional | 2019-11-08 | Terminated (stopped due to Enrollment challenges) | ||
| Vitamin B3 as a Novel Mitochondrial Therapy for Obesity[NCT03951285] | 56 participants (Actual) | Interventional | 2016-05-25 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The safety and tolerability profile of AZD4017 in female patients with IIH through adverse event reporting and safety bloods. (NCT02017444)
Timeframe: 16 weeks
| Intervention | AEs related to intervention (Number) |
|---|---|
| Placebo | 0 |
| AZD4017 (11b-HSD1 Inhibitor) | 9 |
The temporal change in Body Mass Index (in kg/m^2) over 12 weeks of treatment, measured at baseline and week 12 (NCT02017444)
Timeframe: 12 weeks
| Intervention | kg/m^2 (Mean) |
|---|---|
| Placebo | 37.4 |
| AZD4017 (11b-HSD1 Inhibitor) | 37.5 |
The change in headache associated disability through the headache impact test-6 score (HIT 6), measured at baseline and week 12. This is scored 11-66 with higher scores indicating worse headache. (NCT02017444)
Timeframe: 12 weeks
| Intervention | Score on HIT-6 scale (Mean) |
|---|---|
| Placebo | 59.8 |
| AZD4017 (11b-HSD1 Inhibitor) | 60.1 |
ICP measured by lumbar puncture in cmCSF as the change from week 0 and week 12 of treatment, measured at baseline and week 12 (NCT02017444)
Timeframe: 12 weeks
| Intervention | cmCSF (Mean) |
|---|---|
| Placebo | -0.3 |
| AZD4017 (11b-HSD1 Inhibitor) | -4.3 |
The safety and tolerability profile of AZD4017 in female patients with IIH through adverse event reporting and safety bloods. (NCT02017444)
Timeframe: 16 weeks
| Intervention | Serious adverse events (Number) |
|---|---|
| Placebo | 1 |
| AZD4017 (11b-HSD1 Inhibitor) | 0 |
The temporal change in IIH symptoms (presence or absence of diplopia, measured at baseline and week 12 (NCT02017444)
Timeframe: 12 weeks
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Presence | Absence | |
| AZD4017 (11b-HSD1 Inhibitor) | 2 | 15 |
| Placebo | 1 | 11 |
The temporal change in IIH symptoms (presence or absence of headache, measured at baseline and week 12 (NCT02017444)
Timeframe: 12 weeks
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Presence | Absence | |
| AZD4017 (11b-HSD1 Inhibitor) | 13 | 4 |
| Placebo | 10 | 2 |
The temporal change in IIH visual function in both eyes using a Pelli-Robson chart to evaluate log contrast sensitivity between the baseline to week 12 (NCT02017444)
Timeframe: 12 weeks
| Intervention | Log contrast senstivity (Mean) | |
|---|---|---|
| Baseline LCS worst eye | Week 12 LCS worst eye | |
| AZD4017 (11b-HSD1 Inhibitor) | 1.63 | 1.65 |
| Placebo | 1.63 | 1.66 |
The temporal change in OCT Total average retinal nerve fibre layer thickness (μm), measured at baseline and week 12 (NCT02017444)
Timeframe: 12 weeks
| Intervention | μm (Mean) | |
|---|---|---|
| Total average retinal nerve fibre layer baseline worst ete | Total average retinal nerve fibre layer week 12 worst eye | |
| AZD4017 (11b-HSD1 Inhibitor) | 152 | 139.7 |
| Placebo | 158.4 | 143.2 |
"The temporal change in papilloedema (evaluated at the end of trial follow up using stereoscopic fundus photographs by masked neuro-ophthalmologists to grade the images according to Frisen classification) measured at baseline and week 12. There are 6 grades, 0-5, 5 being the worst.~The modified Frisén scale for grading papilledema using fundus photography is as follows:~Grade 1 - C-Shaped halo with a temporal gap~Grade 2 - The halo becomes circumferential~Grade 3 - Loss of major vessels as they leave the disc~Grade 4 - Loss of major vessels on the disc~Grade 5 - Criteria of Grade IV + partial or total obscuration of all vessels on the disc~For further details see e.g. Scott, C.J., et al., Diagnosis and grading of papilledema in patients with raised intracranial pressure using optical coherence tomography vs clinical expert assessment using a clinical staging scale. Arch. Ophthalmol, 2010. 128(6): p. 705-711." (NCT02017444)
Timeframe: 12 weeks
| Intervention | Participants (Count of Participants) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Frisen grade 0 baseline | Frisen grade 0 week 12 | Frisen grade 1 baseline | Frisen grade 1 week 12 | Frisen grade 2 baseline | Frisen grade 2 week 12 | Frisen grade 3 baseline | Frisen grade 3 week 12 | Frisen grade 4 baseline | Frisen grade 4 week 12 | Frisen grade 5 baseline | Frisen grade 5 week 12 | |
| AZD4017 (11b-HSD1 Inhibitor) | 0 | 2 | 4 | 5 | 9 | 8 | 0 | 0 | 2 | 1 | 1 | 0 |
| Placebo | 0 | 0 | 2 | 2 | 5 | 6 | 3 | 3 | 1 | 1 | 0 | 0 |
The temporal change in IIH symptoms (presence or absence of tinnitus), measured at baseline and week 12 (NCT02017444)
Timeframe: 12 weeks
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Presence | Absence | |
| AZD4017 (11b-HSD1 Inhibitor) | 9 | 8 |
| Placebo | 7 | 5 |
The temporal change in IIH visual function in both eyes (measured by LogMAR (log of the minimum angle of resolution) chart to assess visual acuity, between the baseline to week 12, measured at baseline and week 12 (NCT02017444)
Timeframe: 12 weeks
| Intervention | LogMAR (log of the minimum angle of reso (Mean) | |
|---|---|---|
| Baseline LVA worst eye | Week 12 LVA worst eye | |
| AZD4017 (11b-HSD1 Inhibitor) | 0.08 | 0.06 |
| Placebo | 0.13 | 0.09 |
The temporal change in IIH visual function in both eyes using automated perimetry (Humphrey 24-2 central threshold) to measure the visual field mean deviation between the baseline to week 12 (NCT02017444)
Timeframe: 12 weeks
| Intervention | Visual field mean deviation (Mean) | |
|---|---|---|
| Baseline MD worst eye | Week 12 MD worst eye | |
| AZD4017 (11b-HSD1 Inhibitor) | -6.1 | -3.4 |
| Placebo | -3.4 | -2.2 |
The temporal change in IIH symptoms (presence or absence of visual loss, measured at baseline and week 12 (NCT02017444)
Timeframe: 12 weeks
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Presence | Absence | |
| AZD4017 (11b-HSD1 Inhibitor) | 6 | 11 |
| Placebo | 7 | 4 |
The temporal change in IIH symptoms (presence or absence of visual obscuration, measured at baseline and week 12 (NCT02017444)
Timeframe: 12 weeks
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Presence | Absence | |
| AZD4017 (11b-HSD1 Inhibitor) | 2 | 15 |
| Placebo | 2 | 9 |
Difference in Score on the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group - neurotoxicity questionnaire at the end of treatment; i.e. Score at screening - score at end of treatment. This questionnaire asks 11 questions that are specific to chemotherapy-induced peripheral neuropathies. Maximum score is 44, minimum score is 0. Positive differences indicate a decrease in neuropathy. Negative differences indicate a worsening of neuropathy. Zero means unchanged. (NCT03642990)
Timeframe: 4 weeks
| Intervention | units on a scale (Median) |
|---|---|
| NIAGEN®) | 7 |
Exploratory analysis of ability of the clinical version of the Total Neuropathy Score questionnaire to detect changes in CIPN severity over time. Unlike the CTCAE or the FACT&GOG-NTX questionnaires, the TNS is a patient reported outcome measure. HIghest score (worse neuropathy is 24, lowest score is 0. Outcome assessed difference between end of treatment and screening. A positive number indicates improvement in neuropathy (NCT03642990)
Timeframe: 4 weeks
| Intervention | score on a scale (Median) |
|---|---|
| NIAGEN®) | 2 |
Count the number of (i.e. the incidence) of dose reduction events due to neuropathy (each occasion of dose reduction is a separate event); (NCT03642990)
Timeframe: 3 weeks
| Intervention | event (Number) |
|---|---|
| NIAGEN®) | 0 |
"The primary outcome variable is defined as no worsening of the grade of peripheral sensory neuropathy as scored according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 guidelines. Per the CTCAE a score of 1 would be assigned in the instance of parethesias or a loss of deep tendon reflexes. A score of 2 would be assigned in the instance of moderate symptoms that limit instrumental activities of daily living. A score of 3 would be assigned in the instance of severe symptoms that limit self-care activities of daily living. Because the outcome measure is defined as no worsening of the grade, it was recorded as either yes( i.e. it worsened) or no (i.e. it did not worsen)." (NCT03642990)
Timeframe: approximately 4 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| NIAGEN®) | 3 |
Quantitate the percentage of patients that experience a dose reduction of paclitaxel or nab-paclitaxel therapy due to neuropathy. (NCT03642990)
Timeframe: 3 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| NIAGEN®) | 0 |
Paclitaxel levels in plasma were measured ~30 min after each infusion of taxane. This was undertaken to ascertain whether NIAGEN altered plasma levels of paclitaxel because increases or decreases in plasma levels of paclitaxel by itself could lead to an apparent worsening or improvement, respectively, in CIPN and confound interpretation of NIAGEN's effect. (NCT03642990)
Timeframe: up to 3 weeks
| Intervention | ng/ml (Median) |
|---|---|
| NIAGEN®) | 810 |
Quantitate the total cumulative dose of paclitaxel administered over the 12 weeks. (NCT03642990)
Timeframe: 3 weeks
| Intervention | mg/M^2 (Number) |
|---|---|
| NIAGEN®) | 200 |
4 reviews available for niacinamide and Insulin Resistance
| Article | Year |
|---|---|
Nicotinamide N-methyltransferase: At the crossroads between cellular metabolism and epigenetic regulation.
Topics: Adipose Tissue; Animals; Epigenesis, Genetic; Humans; Insulin Resistance; Liver; NAD; Neoplasms; Nia | 2021 |
Nicotinamide riboside, a trace nutrient in foods, is a vitamin B3 with effects on energy metabolism and neuroprotection.
Topics: Alzheimer Disease; Animals; Brain; Disease Models, Animal; Energy Metabolism; Humans; Insulin Resist | 2013 |
Nicotinamide riboside, a trace nutrient in foods, is a vitamin B3 with effects on energy metabolism and neuroprotection.
Topics: Alzheimer Disease; Animals; Brain; Disease Models, Animal; Energy Metabolism; Humans; Insulin Resist | 2013 |
Nicotinamide riboside, a trace nutrient in foods, is a vitamin B3 with effects on energy metabolism and neuroprotection.
Topics: Alzheimer Disease; Animals; Brain; Disease Models, Animal; Energy Metabolism; Humans; Insulin Resist | 2013 |
Nicotinamide riboside, a trace nutrient in foods, is a vitamin B3 with effects on energy metabolism and neuroprotection.
Topics: Alzheimer Disease; Animals; Brain; Disease Models, Animal; Energy Metabolism; Humans; Insulin Resist | 2013 |
Biochemical effects of SIRT1 activators.
Topics: Animals; Cardiotonic Agents; Energy Metabolism; Enzyme Activation; Heterocyclic Compounds, 4 or More | 2010 |
[Pharmacotherapies for type 1 diabetes mellitus].
Topics: Adjuvants, Immunologic; Animals; Biguanides; Chaperonin 60; Diabetes Mellitus, Type 1; Glycoside Hyd | 2002 |
5 trials available for niacinamide and Insulin Resistance
| Article | Year |
|---|---|
Nicotinamide riboside does not alter mitochondrial respiration, content or morphology in skeletal muscle from obese and insulin-resistant men.
Topics: Humans; Insulin Resistance; Male; Middle Aged; Mitochondria, Muscle; Muscle, Skeletal; NAD; Niacinam | 2020 |
11βHSD1 Inhibition with AZD4017 Improves Lipid Profiles and Lean Muscle Mass in Idiopathic Intracranial Hypertension.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adolescent; Adult; Body Composition; Double-Blind Metho | 2021 |
A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects.
Topics: Adult; Aged; Body Composition; Dietary Supplements; Double-Blind Method; Glucose; Humans; Insulin Re | 2018 |
A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects.
Topics: Adult; Aged; Body Composition; Dietary Supplements; Double-Blind Method; Glucose; Humans; Insulin Re | 2018 |
A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects.
Topics: Adult; Aged; Body Composition; Dietary Supplements; Double-Blind Method; Glucose; Humans; Insulin Re | 2018 |
A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects.
Topics: Adult; Aged; Body Composition; Dietary Supplements; Double-Blind Method; Glucose; Humans; Insulin Re | 2018 |
A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects.
Topics: Adult; Aged; Body Composition; Dietary Supplements; Double-Blind Method; Glucose; Humans; Insulin Re | 2018 |
A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects.
Topics: Adult; Aged; Body Composition; Dietary Supplements; Double-Blind Method; Glucose; Humans; Insulin Re | 2018 |
A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects.
Topics: Adult; Aged; Body Composition; Dietary Supplements; Double-Blind Method; Glucose; Humans; Insulin Re | 2018 |
A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects.
Topics: Adult; Aged; Body Composition; Dietary Supplements; Double-Blind Method; Glucose; Humans; Insulin Re | 2018 |
A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects.
Topics: Adult; Aged; Body Composition; Dietary Supplements; Double-Blind Method; Glucose; Humans; Insulin Re | 2018 |
Association of nicotinamide-N-methyltransferase mRNA expression in human adipose tissue and the plasma concentration of its product, 1-methylnicotinamide, with insulin resistance.
Topics: Adult; Aged; Bariatric Surgery; Biomarkers; Case-Control Studies; Cross-Sectional Studies; Diabetes | 2015 |
Nicotinamide's effects on glucose metabolism in subjects at risk for IDDM.
Topics: Adult; Autoantibodies; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 1; Family; Humans; Insulin | 1996 |
41 other studies available for niacinamide and Insulin Resistance
| Article | Year |
|---|---|
Loganin Ameliorates Painful Diabetic Neuropathy by Modulating Oxidative Stress, Inflammation and Insulin Sensitivity in Streptozotocin-Nicotinamide-Induced Diabetic Rats.
Topics: Animals; Antioxidants; Behavior, Animal; Blood Glucose; Body Weight; Calcitonin Gene-Related Peptide | 2021 |
Antidiabetic activity of eupafolin through peroxisome proliferator-activated receptor-gamma and PI3K/Akt signaling in Type 2 diabetic rats.
Topics: Animals; Antioxidants; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Fl | 2023 |
Fucoxanthin-Rich Brown Algae Extract Improves Male Reproductive Function on Streptozotocin-Nicotinamide-Induced Diabetic Rat Model.
Topics: Animals; Antioxidants; Blood Glucose; Cell Survival; Diabetes Mellitus, Experimental; Disease Models | 2019 |
Endogenous nicotinamide riboside metabolism protects against diet-induced liver damage.
Topics: Animals; Blood Glucose; Diet, High-Fat; Disease Models, Animal; DNA Damage; Gene Knockout Techniques | 2019 |
A comparative study of the antidiabetic effect of two training protocols in streptozotocin-nicotinamide diabetic rats.
Topics: Angiopoietin-Like Protein 8; Angiopoietin-like Proteins; Animals; Blood Glucose; Body Weight; Diabet | 2020 |
Mitigating Perspectives of Asiatic Acid in the Renal Derangements of Streptozotocin-Nicotinamide Induced Diabetic Rats.
Topics: Animals; Blood Glucose; Carbohydrate Metabolism; Diabetes Mellitus, Experimental; Gene Expression Re | 2020 |
N
Topics: Acetylation; Animals; Blood Glucose; Cell Line; Diabetes Mellitus, Type 2; Forkhead Box Protein O1; | 2020 |
Long-term atorvastatin or the combination of atorvastatin and nicotinamide ameliorate insulin resistance and left ventricular diastolic dysfunction in a murine model of obesity.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Blood Glucose; Diet, High-Fat; Drug Therapy, Combin | 2020 |
Effect of stevia aqueous extract on the antidiabetic activity of saxagliptin in diabetic rats.
Topics: Adamantane; Animals; Antioxidants; Blood Glucose; Diabetes Mellitus, Experimental; Dipeptides; Herb- | 2021 |
Nicotinamide riboside reduces cardiometabolic risk factors and modulates cardiac oxidative stress in obese Wistar rats under caloric restriction.
Topics: Animals; Antioxidants; Caloric Restriction; Cardiometabolic Risk Factors; Insulin Resistance; Male; | 2020 |
N1‑methylnicotinamide ameliorates insulin resistance in skeletal muscle of type 2 diabetic mice by activating the SIRT1/PGC‑1α signaling pathway.
Topics: Animals; Cell Line; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Insulin Receptor Sub | 2021 |
Effects of exercise training on adipose tissue apelin expression in streptozotocin-nicotinamide induced diabetic rats.
Topics: Adipose Tissue; Animals; Apelin; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabet | 2018 |
Overexpression of NRK1 ameliorates diet- and age-induced hepatic steatosis and insulin resistance.
Topics: Aging; Animals; Diet, High-Fat; Fatty Liver; HEK293 Cells; Humans; Insulin Resistance; Lipid Metabol | 2018 |
Anti-hyperglycemic and anti-hyperlipidemic effects of rhinacanthins-rich extract from Rhinacanthus nasutus leaves in nicotinamide-streptozotocin induced diabetic rats.
Topics: Acanthaceae; Animals; Body Weight; Computer Simulation; Diabetes Mellitus, Experimental; Eating; Gly | 2019 |
Effects of pomegranate aril juice and its punicalagin on some key regulators of insulin resistance and oxidative liver injury in streptozotocin-nicotinamide type 2 diabetic rats.
Topics: Animals; Antioxidants; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Hydrolyzable Tannins; | 2019 |
Nicotinamide supplementation induces detrimental metabolic and epigenetic changes in developing rats.
Topics: Animals; Betaine; Choline; CpG Islands; Dietary Supplements; DNA; DNA Damage; DNA Methylation; Epige | 2013 |
Nicotinamide improves glucose metabolism and affects the hepatic NAD-sirtuin pathway in a rodent model of obesity and type 2 diabetes.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Disease Models, | 2014 |
Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity.
Topics: Acetyltransferases; Adipocytes; Adipose Tissue; Adipose Tissue, White; Animals; Diabetes Mellitus, T | 2014 |
Antidiabetic activity of benzopyrone analogues in nicotinamide-streptozotocin induced type 2 diabetes in rats.
Topics: Animals; Biomarkers; Blood Glucose; Coumarins; Creatinine; Diabetes Mellitus, Experimental; Diabetes | 2014 |
Resveratrol activates duodenal Sirt1 to reverse insulin resistance in rats through a neuronal network.
Topics: Animals; Antioxidants; Blood Glucose; Diabetes Mellitus; Disease Models, Animal; Gene Expression Reg | 2015 |
Metformin activates a duodenal Ampk-dependent pathway to lower hepatic glucose production in rats.
Topics: AMP-Activated Protein Kinases; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Duodenum; Gene Exp | 2015 |
Management of nicotinamide N-methyltransferase overexpression: inhibit the enzyme or reduce nicotinamide intake? Reply to Zhou S, Li D, Zhou Y [letter].
Topics: Diabetes Mellitus, Type 2; Female; Humans; Insulin Resistance; Male; Niacinamide; Nicotinamide N-Met | 2015 |
Management of nicotinamide N-methyltransferase overexpression: inhibit the enzyme or reduce nicotinamide intake?
Topics: Diabetes Mellitus, Type 2; Female; Humans; Insulin Resistance; Male; Niacinamide; Nicotinamide N-Met | 2015 |
Time Course of Molecular and Metabolic Events in the Development of Insulin Resistance in Fructose-Fed Rats.
Topics: Animals; Carbohydrate Metabolism; Fructose; Hyperglycemia; Insulin Resistance; Lipid Metabolism; Liv | 2016 |
Nicotinamide Riboside Opposes Type 2 Diabetes and Neuropathy in Mice.
Topics: Animals; Blood Glucose; Cornea; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Diet, High-F | 2016 |
Nicotinamide Riboside Opposes Type 2 Diabetes and Neuropathy in Mice.
Topics: Animals; Blood Glucose; Cornea; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Diet, High-F | 2016 |
Nicotinamide Riboside Opposes Type 2 Diabetes and Neuropathy in Mice.
Topics: Animals; Blood Glucose; Cornea; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Diet, High-F | 2016 |
Nicotinamide Riboside Opposes Type 2 Diabetes and Neuropathy in Mice.
Topics: Animals; Blood Glucose; Cornea; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Diet, High-F | 2016 |
The anti-diabetic activity of oat β-d-glucan in streptozotocin-nicotinamide induced diabetic mice.
Topics: Animals; beta-Glucans; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Drinking; Fastin | 2016 |
Long-term treatment with nicotinamide induces glucose intolerance and skeletal muscle lipotoxicity in normal chow-fed mice: compared to diet-induced obesity.
Topics: Animals; Antioxidants; Autophagy; Diet, High-Fat; Dietary Supplements; Gene Expression Regulation; G | 2016 |
Chronic inhibition of dipeptidyl peptidase-IV with ASP8497 improved the HbA(1c) level, glucose intolerance, and lipid parameter level in streptozotocin-nicotinamide-induced diabetic mice.
Topics: Administration, Oral; Animals; Diabetes Mellitus, Experimental; Dipeptidyl-Peptidase IV Inhibitors; | 2009 |
Construction of adiponectin-encoding plasmid DNA and gene therapy of non-obese type 2 diabetes mellitus.
Topics: Adiponectin; Animals; Blood Glucose; Cell Line; Cell Line, Tumor; Diabetes Mellitus, Experimental; D | 2010 |
Chronic niacin overload may be involved in the increased prevalence of obesity in US children.
Topics: Adolescent; Adult; Appetite; Biomarkers; Blood Glucose; Child; Child, Preschool; Feeding Behavior; G | 2010 |
Effects of antidiabetic drugs in high-fat diet and streptozotocin-nicotinamide-induced type 2 diabetic mice.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dietary Fats; Drug Administrati | 2011 |
Decreased skin-mediated detoxification contributes to oxidative stress and insulin resistance.
Topics: Animals; Antioxidants; Blood Glucose; Burns; Glycogen; Hydrogen Peroxide; Insulin; Insulin Resistanc | 2012 |
The methanolic fraction of Centratherum anthelminticum seed downregulates pro-inflammatory cytokines, oxidative stress, and hyperglycemia in STZ-nicotinamide-induced type 2 diabetic rats.
Topics: Animals; Antioxidants; Asteraceae; Cells, Cultured; Cytokines; Diabetes Mellitus, Type 2; Hyperglyce | 2012 |
Excessive nicotinic acid increases methyl consumption and hydrogen peroxide generation in rats.
Topics: Animals; Dose-Response Relationship, Drug; Glucose; Glucose Tolerance Test; Glycogen; Hydrogen Perox | 2013 |
Meliacinolin: a potent α-glucosidase and α-amylase inhibitor isolated from Azadirachta indica leaves and in vivo antidiabetic property in streptozotocin-nicotinamide-induced type 2 diabetes in mice.
Topics: alpha-Amylases; Animals; Azadirachta; Biomarkers; Blood Glucose; Diabetes Mellitus, Experimental; Di | 2012 |
Changes in hepatic lipogenic and oxidative enzymes and glucose homeostasis induced by an acetyl-L-carnitine and nicotinamide treatment in dyslipidaemic insulin-resistant rats.
Topics: Acetyl-CoA Carboxylase; Acetylcarnitine; Animals; Body Weight; Carnitine O-Palmitoyltransferase; Dis | 2013 |
Insulinotropic agent ID-1101 (4-hydroxyisoleucine) activates insulin signaling in rat.
Topics: Animals; Diabetes Mellitus, Experimental; Diet; Enzyme Activation; Glucose; Glucose Clamp Technique; | 2004 |
Establishment and pathophysiological characterization of type 2 diabetic mouse model produced by streptozotocin and nicotinamide.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dietary Fats; Do | 2006 |
Sexual dimorphism in insulin sensitivity and susceptibility to develop diabetes in rats.
Topics: Animals; Biomarkers; Blood Glucose; Body Composition; Diabetes Mellitus, Experimental; Disease Susce | 2006 |
Insulin resistance and progression to type 1 diabetes in the European Nicotinamide Diabetes Intervention Trial (ENDIT).
Topics: Adolescent; Autoimmunity; Child; Cohort Studies; Diabetes Mellitus, Type 1; Disease Progression; Eur | 2008 |
Effect of partial pancreatectomy on beta-cell mass in the remnant pancreas of Wistar fatty rats.
Topics: Animals; Blood Glucose; Cell Division; Diabetes Mellitus; Diabetes Mellitus, Type 2; Disease Models, | 1998 |